rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Profound Medical Corp.

PROF · Nasdaq

Health CareMedical DevicesNot moving yet

PROF stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 11 weeks. It is 9.5% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 11
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
4
Institutions holding
57 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$97KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k21 Jul 2020filed 5 Mar 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k27 Jan 2020filed 26 Aug 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k14 Jan 2020filed 26 Aug 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k20 Dec 2019filed 5 Mar 2021

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders57+1 on the quarter
New · exited6 · 6
Reported value$105.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FIL Ltdadded · filed 13 Aug 20262,370,000$15.8M+30,000+1.3%
GAGNON SECURITIES LLCadded · filed 5 Aug 20261,960,074$13.0M+15,750+0.8%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20261,199,564$8.0M+83,216+7.5%
Timelo Investment Management Inc.unchanged · filed 13 Aug 20261,114,967$7.4M00.0%
Gagnon Advisors, LLCunchanged · filed 5 Aug 2026962,186$6.4M00.0%
LETKO, BROSSEAU & ASSOCIATES INCreduced · filed 13 Aug 2026935,725$5.4M-17,450−1.8%
Rosalind Advisors, Inc.unchanged · filed 14 Aug 2026828,118$5.5M00.0%
Z3 Capital Partners, LLCadded · filed 28 Jul 2026820,941$5.5M+2,950+0.4%
MMCAP International Inc. SPCreduced · filed 14 Aug 2026671,356$4.5M-73,796−9.9%
ARDSLEY ADVISORY PARTNERS LPunchanged · filed 13 Jul 2026575,000$3.8M00.0%
31 Mar 2023 – 30 Jun 2026
294561Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Arun Swarup Menawat Company insiderCEO · last 16 May 20252 · 0
Tom Malinowski HouseNJ07 · last 21 Jul 20204 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202570.8%
Operating profit marginFY 2025 · to 31 Dec 2025-256%
Free cash flow marginFY 2025 · to 31 Dec 2025-238%
Return on capital employedFY 2025 · to 31 Dec 2025-57.8%
Debt to equityFY 2025 · to 31 Dec 20250.07×
Research spendFY 2025 · to 31 Dec 2025128%
Share count trendFY 2025 · to 5 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$59.7M
Free cash flowFY 2025 · to 31 Dec 2025−$38.4M

Analyst forecasts

No analyst forecasts yet.